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Exslanatory Memorandum 
1. On 4 December 1980, the Commission put forward a proposal for a 
Directive to the Council amending Directives 65/65/EEC, 75/318/EEC and 
75/319/EEC on the approximation of provisions laid down by law, 
regulation or administrative action relating to proprietary medicinal 
products (OJ C 355, 31.12.1980). 
2o In conformity with Article 100 of the Treaty the Economic and Social 
Committee and the European Parliament adopted an opinion on the 
proposal on 29 June 1981 (doe. CES 676/81) and 16 October 1981 (Doe. 
P.E. 74.859) respectivelyo These opinions contained certain amendments. 
3. The Commission is willing to accept certain of these amendments and 
proposes the following amendments to its proposal: 
-In the English text, substitute the expression 'data-sheet' 
for 'product-summary'. 
-Article 1: 
paragraph 2, points 5.7 and 5.10 
paragraph 5. 
-Article 2, paragraph 2. 
- Article 3 
"Article 9, point 3 
Article 13, point 1 
Article 14, point 1. " 
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Amendment to the proposal for a Co~ncit Directive amending Directives 
~ .. '~§.~.cL 75/318/EEC and 75/3'19/EEC on the approximation of provisions 
Laid down by Law, regulst1on or administr~tive &et1on reLating to 
proprietary medicinal products 
1. In the EngLish version the expression 'data-sheet' which appears in 
the 3rd recital as well as in Article 1, paragraph 2, 2nd subparagraph, 
and paragraph 3, 2nd and 4th subparagraphp shall be replaced by the 
expression 'product-summary'. 
2. Article 1, paragraph 2, shall be amended as follows: 
5.7 Posology and method of administration for children and 
adults respectivell 
5.10 Effect on abHitt..J:_o dr'ive a vehicle and operate machinery 
3. Article 1, paragraph 5, shall be amended as follows: 
The following Article 9a shall be ~nserted after Article 9: 
"After an authorization has be€·n issued, the person respons·i b le 
for placing the product on the market must, in respect of the 
control method provided for in Article 4, point 7, take account 
of technical and scientific progress and introduce any changes 
that may be required to enable the proprietary medicinal product 
to be checked in accordanc.e with generally recognized scientific 
methods." 
4. Article 2, paragraph 2, shall be amended as follows: 
In part I, C, the following paragraph 3 shall be inserted: 
"3. Physico-chemical characterist·ics liable to affect bio-availability 
The following items of information concerning act~ve principles, 
whether or not listed in the pharmacopoeias, shall be provided 
as part of the general description of the active principles if 
they relate to the bio-availability of the medicinal product: 
-crystalline form and solubility coefficients, 
- particle size~ where necessary after pulverization, 
- state of hydration, 
-oil/water partition coefficientp 
the requirements of the first three indents not being applicable 
to substances used solely in solution." 
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lt 5. Article 3 shall be amended as follows: 
"Article 9 
3. The Committee shall forward this information immediately to 
the Member States. 
Article 13 
1. In order to facilitate any discussions by the Committee, the 
competent authorities shall draw up a report to assess the · 
results of the analytical and toxico-pharmacological tests and 
clinical trials of any propr~etary product containing a new 
active substance which is the subject of an application for a 
marketing authorization in the Member States concerned for the 
first time or of any other proprietary product that they may 
choose, particularly when the hoLder o"f_the marketing authorizatior. 
whi_s_h~s-·~o follow t_he E?rocedure desc.ri bed in ArticLe ~= 
Article 14 
1. When reference is made to the procedure described in this 
Article, the Committee shall consider the matter and express a 
reasoned opinion within 60 days of the date on which the matter 
was referred to it. 
The person responsible for Blacing the product on the market 
may, at his request, explain himself_verbally or in writing 
before the Committee ft_xpresses its opinion. He may also obtain 
the suspension of the above-mentioned time Limit." 
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